SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-22-004206
Filing Date
2022-06-07
Accepted
2022-06-07 16:53:21
Documents
13
Period of Report
2022-06-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_060722.htm   iXBRL 8-K 35502
2 EXHIBIT 10.1 exh_101.htm EX-10.1 135027
  Complete submission text file 0001171843-22-004206.txt   374879

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bcrx-20220607.xsd EX-101.SCH 2959
4 XBRL LABEL FILE bcrx-20220607_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE bcrx-20220607_pre.xml EX-101.PRE 22359
7 EXTRACTED XBRL INSTANCE DOCUMENT f8k_060722_htm.xml XML 3582
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 221001749
SIC: 2836 Biological Products, (No Diagnostic Substances)